Baudax Bio, Inc.

Baudax Bio Initiates Phase IV Clinical Trial Evaluating ANJESO in Pediatric Patients Following Surgery

MALVERN, PA — Baudax Bio, Inc. (NASDAQ: BXRX) recently announced the initiation of a clinical study evaluating the safety and pharmacokinetics (PK) of ANJESO (meloxicam) injection in pediatric patients (ages …

Baudax Bio Initiates Phase IV Clinical Trial Evaluating ANJESO in Pediatric Patients Following Surgery Read More